Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20701195 | 1.00 | USP30 (0.42) | USP30NR1H2NR1H3UCHL1CTSB | |
| SCHEMBL20701193 | 1.00 | USP30 (0.42) | USP30NR1H2NR1H3UCHL1CTSB | |
| SCHEMBL26563034 | 0.94 | USP30 (0.47) | USP30NR1H2NR1H3UCHL1MAPT | |
| SCHEMBL29418103 | 0.94 | USP30 (0.47) | USP30NR1H2NR1H3UCHL1MAPT | |
| SCHEMBL29330072 | 0.88 | USP30 (0.43) | USP30NR1H2NR1H3UCHL1CTSB | |
| SCHEMBL8273912 | 0.87 | GRM5 (0.46) | USP30NR1H2NR1H3UCHL1MAPT | |
| SCHEMBL13344514 | 0.87 | GRM5 (0.46) | USP30NR1H2NR1H3UCHL1MAPT | |
| SCHEMBL8273946 | 0.87 | GPR119 (0.48) | NR1H2NR1H3CTSSCTSKMAPT | |
| SCHEMBL13344519 | 0.87 | GPR119 (0.48) | NR1H2NR1H3CTSSCTSKMAPT | |
| SCHEMBL13344505 | 0.86 | NR1H2 (0.45) | NR1H2NR1H3KLK7KMT2ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239744-A1 | 2-(3-ETHYNYLBENZYL)-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | OXFORD FINANCE LLC | 2024-07-18 | — | — | US | disclosed |
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | disclosed |
| EP-3816153-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-11655241-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-23 | — | — | US | disclosed |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022207935-A1 | 2-(3-ETHYNYLBENZYL)-SUBSTITUTED HETEROCYCLE DERIVATIVES AS OREXIN-2 AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| US-11440883-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-13 | — | — | US | disclosed |
| US-20210198240-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3816153-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3661923-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-10584097-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-10 | — | — | US | disclosed |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-16 | — | — | US | disclosed |
| US-10428023-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | disclosed |
| WO-2019027058-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-11655241-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, MCHR2 | USP30 4365/4885NR1H2 84/4885NR1H3 113/4885 |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-11440883-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-20240239744-A1 | 2-(3-ETHYNYLBENZYL)-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | HCRTR2, CRHR2, HCRTR1 | USP30 3432/4885NR1H2 30/4885NR1H3 46/4885 |
| US-20210198240-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | USP30 4365/4885NR1H2 84/4885NR1H3 113/4885 |
| US-10428023-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-10584097-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | USP30 4217/4885NR1H2 73/4885NR1H3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.